Aspirin
Bamlanivimab
Bromhexine
Budesonide
Casirivimab/i..
Colchicine
Conv. Plasma
Curcumin
Favipiravir
Fluvoxamine
Hydroxychloro..
Iota-carragee..
Ivermectin
Melatonin
Molnupiravir
Nigella Sativa
Nitazoxanide
Povidone-Iod..
Probiotics
Proxalutamide
Quercetin
Remdesivir
Sotrovimab
Vitamin A
Vitamin C
Vitamin D
Zinc

Other
Feedback
Home
Top
All studies
Exclusions
Mortality
ICU
Serious outcomes
Cases
Peer-reviewed
All outcomes

Feedback
Home   COVID-19 treatment studies for Vitamin A  COVID-19 treatment studies for Vitamin A  C19 studies: Vitamin A  Vitamin A   Select treatmentSelect treatmentTreatmentsTreatments
Aspirin Molnupiravir
Bamlanivimab Nigella Sativa
Bromhexine Nitazoxanide
Budesonide Povidone-Iod..
Casirivimab/i.. Probiotics
Colchicine Proxalutamide
Conv. Plasma Quercetin
Curcumin Remdesivir
Favipiravir Sotrovimab
Fluvoxamine Vitamin A
Hydroxychloro.. Vitamin C
Iota-carragee.. Vitamin D
Ivermectin Zinc
Melatonin

Other Adoption
Outcomes in COVID-19 vitamin A studies
00.250.50.7511.251.51.752+Al-Sumiadai86%0.14 [0.03-0.61]death2/7014/70Improvement, RR [CI]TreatmentControlAl-Sumiadai67%0.33 [0.07-1.57]progression2/506/50Tau​2 = 0.00; I​2 = 0.0%Early treatment79%0.21 [0.07-0.61]4/12020/12079% improvementSarohan-282%3.83 [1.58-9.24]death9/104/17Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%Late treatment-282%3.83 [1.58-9.24]9/104/17-282% improvementAl-Sumiadai64%0.36 [0.23-0.54]cases20/9765/112Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%PEP64%0.36 [0.23-0.54]20/9765/11264% improvementTomasa-Irriguible71%0.29 [0.10-0.67]ventilation4/3448/86Improvement, RR [CI]TreatmentControlTepasse70%0.30 [0.07-0.97]death4/295/11Tau​2 = 0.00; I​2 = 0.0%Sufficiency71%0.29 [0.14-0.60]8/6353/9771% improvementAll studies55%0.45 [0.18-1.10]41/290142/34655% improvement6 vitamin A COVID-19 studiesc19early.com/va Sep 24, 2021Tau​2 = 0.97; I​2 = 82.0%; Z = 1.75Effect extraction pre-specifiedFavors vitamin AFavors control 00.250.50.7511.251.51.752+Al-Sumiadai67%0.33 [0.07-1.57]progression2/506/50Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%Early treatment67%0.33 [0.07-1.57]2/506/5067% improvementAl-Sumiadai64%0.36 [0.23-0.54]cases20/9765/112Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%PEP64%0.36 [0.23-0.54]20/9765/11264% improvementTomasa-Irriguible71%0.29 [0.10-0.67]ventilation4/3448/86Improvement, RR [CI]TreatmentControlTepasse70%0.30 [0.07-0.97]death4/295/11Tau​2 = 0.00; I​2 = 0.0%Sufficiency71%0.29 [0.14-0.60]8/6353/9771% improvementAll studies66%0.34 [0.24-0.48]30/210124/25966% improvement4 vitamin A COVID-19 studies after exclusionsc19early.com/va Sep 24, 2021Tau​2 = 0.00; I​2 = 0.0%; Z = 6.01Effect extraction pre-specifiedFavors vitamin AFavors control 00.250.50.7511.251.51.752+Al-Sumiadai86%0.14 [0.03-0.61]2/7014/70Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%Early treatment86%0.14 [0.03-0.61]2/7014/7086% improvementSarohan-282%3.83 [1.58-9.24]9/104/17Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%Late treatment-282%3.83 [1.58-9.24]9/104/17-282% improvementTepasse70%0.30 [0.07-0.97]4/295/11Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%Sufficiency70%0.30 [0.07-0.97]4/295/1170% improvementAll studies42%0.58 [0.07-4.59]15/10923/9842% improvement3 vitamin A COVID-19 mortality resultsc19early.com/va Sep 24, 2021Tau​2 = 2.99; I​2 = 90.1%; Z = 0.52Favors vitamin AFavors control 00.250.50.7511.251.51.752+Tomasa-Irriguible61%0.39 [0.15-0.80]6/3454/86Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%Sufficiency61%0.39 [0.15-0.80]6/3454/8661% improvementAll studies61%0.39 [0.18-0.81]6/3454/8661% improvement1 vitamin A COVID-19 ICU resultc19early.com/va Sep 24, 2021Tau​2 = 0.00; I​2 = 0.0%; Z = 2.50Favors vitamin AFavors control 00.250.50.7511.251.51.752+Al-Sumiadai86%0.14 [0.03-0.61]death2/7014/70Improvement, RR [CI]TreatmentControlAl-Sumiadai67%0.33 [0.07-1.57]progression2/506/50Tau​2 = 0.00; I​2 = 0.0%Early treatment79%0.21 [0.07-0.61]4/12020/12079% improvementSarohan-282%3.83 [1.58-9.24]death9/104/17Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%Late treatment-282%3.83 [1.58-9.24]9/104/17-282% improvementTomasa-Irriguible71%0.29 [0.10-0.67]ventilation4/3448/86Improvement, RR [CI]TreatmentControlTepasse70%0.30 [0.07-0.97]death4/295/11Tau​2 = 0.00; I​2 = 0.0%Sufficiency71%0.29 [0.14-0.60]8/6353/9771% improvementAll studies54%0.46 [0.13-1.65]21/19377/23454% improvement5 vitamin A COVID-19 serious outcomesc19early.com/va Sep 24, 2021Tau​2 = 1.75; I​2 = 84.1%; Z = 1.19Effect extraction pre-specifiedFavors vitamin AFavors control 00.250.50.7511.251.51.752+Al-Sumiadai64%0.36 [0.23-0.54]20/9765/112Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%PEP64%0.36 [0.23-0.54]20/9765/11264% improvementAll studies64%0.36 [0.23-0.54]20/9765/11264% improvement1 vitamin A COVID-19 case resultc19early.com/va Sep 24, 2021Tau​2 = 0.00; I​2 = 0.0%; Z = 4.82Favors vitamin AFavors control 00.250.50.7511.251.51.752+Al-Sumiadai86%0.14 [0.03-0.61]death2/7014/70Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%Early treatment86%0.14 [0.03-0.61]2/7014/7086% improvementTomasa-Irriguible71%0.29 [0.10-0.67]ventilation4/3448/86Improvement, RR [CI]TreatmentControlTepasse70%0.30 [0.07-0.97]death4/295/11Tau​2 = 0.00; I​2 = 0.0%Sufficiency71%0.29 [0.14-0.60]8/6353/9771% improvementAll studies75%0.25 [0.13-0.48]10/13367/16775% improvement3 vitamin A COVID-19 peer reviewed trialsc19early.com/va Sep 24, 2021Tau​2 = 0.00; I​2 = 0.0%; Z = 4.17Effect extraction pre-specifiedFavors vitamin AFavors control 00.250.50.7511.251.51.752+Al-Sumiadai86%0.14 [0.03-0.61]death2/7014/70Improvement, RR [CI]TreatmentControlAl-Sumiadai67%0.33 [0.07-1.57]progression2/506/50Sarohan-282%3.83 [1.58-9.24]death9/104/17Al-Sumiadai64%0.36 [0.23-0.54]cases20/9765/112Tomasa-Irriguible71%0.29 [0.10-0.67]ventilation4/3448/86Tomasa-Irriguible61%0.39 [0.15-0.80]ICU6/3454/86Tepasse70%0.30 [0.07-0.97]death4/295/11Tepasse45%0.55 [0.16-1.00]progression13/299/11vitamin A COVID-19 outcomesc19early.com/va Sep 24, 2021Favors vitamin AFavors control
Please send us corrections, updates, or comments. Vaccines and treatments are both extremely valuable and complementary. All practical, effective, and safe means should be used. Elimination of COVID-19 is a race against viral evolution. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases the risk of COVID-19 becoming endemic; and increases mortality, morbidity, and collateral damage. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. Treatment protocols for physicians are available from the FLCCC.
  or use drag and drop   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit